An Austin-based energy software company just scored funding from Houston investors. Photo via Getty Images

Houston-based investment firm Goose Capital led a $3.25 million round of seed funding revealed recently by Austin-based cleantech software company P6 Technologies.

Other participants in the round are Houston-based investment firms Artemis Energy Partners, Tupper Lake Partners, and Veritec Ventures. The seed round represents the first outside funding for P6, which maintains an office in Houston.

In conjunction with the seed funding:

  • Artemis founder and CEO Bobby Tudor has joined P6’s board of directors. He is an investor in Goose Capital.
  • Paal Kibsgaard, managing partner of Veritec, also has joined the P6 board. Kibsgaard is former chairman and CEO of Houston-based oilfield services company Schlumberger, which now does business as SLB.

Joe Berti, CEO of P6, says Kibsgaard’s “unparalleled experience” will benefit his company.

“Veritec’s strategic vision and active support of energy transition solutions align perfectly with our goals, and I am confident their contribution will be instrumental in shaping our future success,” Berti says in a news release.

Berti is former chief product officer of IBM’s sustainability software unit.

P6, founded in 2022, sells enterprise software to businesses in the energy, transportation fuel, and petrochemical sectors. The startup’s software for product lifecycle assessment enables measurement of the product-level intensity of greenhouse gas (GHG) emissions as energy companies try to achieve sustainability goals.

Tudor applauds P6 for helping fossil fuel-anchored companies reduce GHG emissions.

“Energy is the sector that needs a solution like P6 the most,” says Tudor. “P6 has the right approach and is going to make a step-change improvement to how product-level carbon intensity and GHG emissions are tracked today.”

------

This article originally ran on EnergyCapital.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”